Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (20)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Sculier, J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sculier, J. P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 10:295-303, 1999
© 1999 European Society for Medical Oncology

research-article

A randomised phase III trial comparing consolidation treatment with further chemotherapy to chest irradiation in patients with initially unresectable locoregional non-small-cell lung cancer responding to induction chemotherapy

J. P. Sculier, M. Paesmans, J. J. Lafitte, J. Baumöhl, J. Thiriaux, O. van Cutsem, P. Recloux, G. Bureau, M. C. Berchier, C. Zacharias, P. Mommen, T. Bosschaerts, T. Berghmans, P. van Houtte, V. Ninane and J. Klastersky for the European Lung Cancer Working Party

Service de Médecine, Institut Jules Bordet Brussels, Belgium

Purpose: A phase III randomised trial was conducted in patients with non-metastatic unresectable non-small-cell lung cancer in order to compare, in responders to induction chemotherapy, consolidation treatment by further chemotherapy to chest irradiation.

Patients and methods: A total of 462 untreated NSCLC patients were eligible for three courses of induction chemotherapy (MIP) consisting of cisplatin (50 mg/m2), ifosfamide (3 g/m2) and mitomycin C (6 mg/m2). It was proposed that objective responders be randomised to either three further courses of MIP or to chest irradiation (60 Gy; 2 Gy per fraction given over six weeks).

Results: An objective response rate of 35% was achieved; 115 patients (including 52% with initial stage IIIA and 44% with initial stage IIIB) were randomised to consolidation treatment, 60 of them to further chemotherapy and 55 to chest radiotherapy. There was no significant difference in survival between the two arms, with a respective median and two-year survival of 42 weeks (95% confidence intervals (95% CI): 35–51) and 18% (95% CI: 8–28) for chemotherapy and 54 weeks (95% CI: 43–73) and 22% (95% CI: 11–33) for irradiation. There was also no statistical difference for response duration between the two arms but chest irradiation was associated with a significantly greater duration of local control than chemotherapy (median duration times: 158 vs. 31 weeks, P = 0.0007).

Conclusions: For non-metastatic unresectable NSCLC treated by an induction chemotherapy regimen containing cisplatin and ifosfamide, if an objective response is obtained, consolidation treatments by further chemotherapy or by chest irradiation result in non-statistically different survival distributions, although a better local control duration is observed with radiotherapy.

chest irradiation, induction chemotherapy, loco-regional disease, non-small-cell lung cancer, randomised trial


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur Respir JHome page
J. P. Sculier, J. J. Lafitte, M. Paesmans, J. Lecomte, C. G. Alexopoulos, O. Van Cutsem, V. Giner, A. Efremidis, M. C. Berchier, T. Collon, et al.
Chemotherapy improves low performance status lung cancer patients
Eur. Respir. J., December 1, 2007; 30(6): 1186 - 1192.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. Berghmans and J.P. Sculier
Is the Tolerance to MIP Chemotherapy Different Between English and Other European Populations?
J. Clin. Oncol., September 1, 2005; 23(25): 6269 - 6270.
[Full Text] [PDF]

Home page
 JCOHome page
R.M. Rudd, N.H. Gower, S.G. Spiro, S.M. Lee, T.G. Eisen, P.G. Harper, M. Hatton, W.M.C. Martin, and E.M. Rankin
In Reply:
J. Clin. Oncol., September 1, 2005; 23(25): 6270 - 6271.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. Thatcher, C. Faivre-Finn, F. Blackhall, H. Anderson, and P. Lorigan
Sequential Platinum-Based Chemotherapy-Thoracic Radiotherapy in Early Stage Non-Small Cell Lung Cancer
Clin. Cancer Res., July 1, 2005; 11(13): 5051s - 5056s.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
T. Berghmans, A. P. Meert, B. Martin, V. Ninane, and J. P. Sculier
Prognostic role of epidermal growth factor receptor in stage III nonsmall cell lung cancer
Eur. Respir. J., February 1, 2005; 25(2): 329 - 335.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J.-P. Sculier, J.-J. Lafitte, T. Berghmans, P. Van Houtte, J. Lecomte, J. Thiriaux, A. Efremidis, G. Koumakis, V. Giner, M. Richez, et al.
A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional non-small-cell lung cancer
Ann. Onc., March 1, 2004; 15(3): 399 - 409.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.